Back to Clinical Trials Overview

Your search for "Infectious Diseases" returned 25 results:


Management Practices and the Risk of Infection Following Cardiac Surgery
Principal Investigator(s): Gelijns, Annetine

Treatment of Hepatitis C in Primary Care Setting
Principal Investigator(s): McGinn, Thomas

Evaluating Conventional & High Does Oseltamivir
Principal Investigator(s): Lief, Michael

Tenofovir Disoproxil Fumarate v. Emtricitabine for Hep B
Principal Investigator(s): Liu, Lawrence

Hepatitis C Primary Care Cohort
Principal Investigator(s): McGinn, Thomas

A Rollover Protocol to Provide Open-Label Emtricitabine/Tenofovir Disoproxil Fumarate Combination Product to Subjects Completing the GS-US-203-0107 Study. Protocol GS-US-203-0109
Principal Investigator(s): Schiano, Thomas

Comparative Study of Hepatitis B Pts:The BE-LOW Study
Principal Investigator(s): Dieterich, Douglas

The effect of non-ulcerative sexually transmitted infections on cervico-vaginal microbes and cervico-vaginal immune response
Principal Investigator(s): Sperling, Rhoda S, MD

Efficacy & Safety of Drotrecogin Alfa (Activated) in Adult Patients with Septic Shock
Principal Investigator(s): Oropello, John M

Intracellular Antivirals:New Direction in HIV Control
Principal Investigator(s): Simon, Viviana

Studies of Ocular Complications of AIDS
Principal Investigator(s): Jabs, Douglas A

2 Dose Regimens of Telaprevir in Comb. w/Pegasys&Copegus
Principal Investigator(s): Dieterich, Douglas

Evaluation of Tenofovir DF vs. Adefovir Dipivoxil
Principal Investigator(s): Odin, Joseph A

Eritoran Tetrasodium and Placebo in Patients/Severe Sepsis
Principal Investigator(s): Kholi-Seth, Roopa

A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment -Naive Subjects with Genotype 1 Chronic Hepatitis C who Achieve an Extended Rapid Viral Response (eRVR) while Receiving Telaprevir, Peginterferon Alfa2a (Pegasys) and Ribavirin (Copegus) [VX08-950-111]
Principal Investigator(s): Dieterich, Douglas

Characterization of Acute HCV Infection
Principal Investigator(s): Fierer, Daniel S

Tenofovir DF vs. Adefovir Dipivoxil Chronic Hepatitis
Principal Investigator(s): Odin, Joseph A

Can Varicella Zoster Virus (VZV) DNA be Detected in Paraffin Tissue Sections?
Principal Investigator(s): Harpaz, Noam

The Epidemiology of Ventricular Assist Device-Related Infections
Principal Investigator(s): Parides, Michael

Cervical, Anal & Oral HPV Persistence/Adolescent Girls
Principal Investigator(s): Diaz, Angela MD, MPH

Telaprevir (VX-950) Pegasys & Copegus in Hepatitis C
Principal Investigator(s): Dieterich, Douglas

Immune Response to Virus During Pregnacny (VIP-003)
Principal Investigator(s): Sperling, Rhoda S, MD

A Phase 2b Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24, or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 weeks of Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic Hepatitis C Virus (HCV) Infection
Principal Investigator(s): Odin, Joseph A

Antiviral Effect, Safety, & Pharmacokinetics of once Daily BI 201335 NA in Hepatitis C Virus Genotype 1 Infected Treatment-Naive Patients for 24 weeks as Combination Therapy with Pegylated Interferon-a 2a and Ribavirin
Principal Investigator(s): Dieterich, Douglas

Center for Investigating Viral Immunity & Antagonism
Principal Investigator(s): Moran, Thomas M